Shanghai Plans Full-Chain Oversight for Brain-Computer Interface Medical Devices

Shanghai has ordered regulators to build a full-chain service and supervision framework for brain-computer interface (BCI, devices that record or modulate neural signals to drive external systems) medical devices, according to a municipal planning document reported by 36Kr on the day of publication.

The Shanghai Food and Drug Safety Committee issued the plan, titled the "Shanghai '15th Five-Year' Plan for Safeguarding Drug Safety and Promoting High-Quality Development of the Pharmaceutical Industry." The document directs authorities to strengthen pre-market supervision of BCI medical devices and to accelerate product launches and clinical application.

What does the plan actually specify?

The document sets out four concrete regulatory workstreams for the BCI device sector:

• Pre-market supervision. Shanghai will refine the regulatory system governing BCI medical devices before they reach the market.
• Dedicated standards. The city will build and improve a standards system specific to BCI medical devices, a category that currently lacks a mature, dedicated technical framework in China.
• Micro-nano electrode testing. Regulators will develop evaluation methods for the new functions and new characteristics of micro- and nano-scale neural electrodes (miniaturized implants or interfaces that contact neural tissue at microscopic scale), together with the test fixtures and tooling needed to verify them.
• Linked review and monitoring. Shanghai will establish a "research–testing–review–supervision" linkage mechanism, connecting premarket review and approval, inspection and testing, and post-market risk monitoring.

The stated goal of that linkage is to compress the path from laboratory to registered product, speeding market entry and real-world use of BCI devices.

Why does the neural electrode clause matter for device developers?

The explicit reference to micro-nano neural electrode evaluation methods signals where Shanghai expects technical bottlenecks to sit. Electrode performance — signal fidelity, durability, biocompatibility behavior over time — is difficult to characterize under general-purpose device standards. Purpose-built test methods and evaluation fixtures would give manufacturers a defined acceptance pathway and give reviewers a consistent basis for judging novel electrode designs before clinical use.

No specific product categories, clinical indications or companies are named in the document. The plan is a policy framework, not a device approval, and no BCI product is cleared or authorized by the text itself.

What else does the plan change for the wider device industry?

The same document lays out a broader reform agenda for medical devices that will shape the operating environment for neurotechnology companies registered or manufacturing in Shanghai:

• In-house IVD pilot. Medical institutions are encouraged to accelerate pilot work on in vitro diagnostic reagents they develop and use themselves, and to convert registered self-developed reagents into formally registered IVD products.
• Pre-submission dialogue. Innovative devices qualifying for national priority review will receive pre-filing communication services on registration applications.
• Site-change streamlining. Companies already holding domestic device registration certificates will find it easier to manufacture Class II and Class III devices in Shanghai after site changes.
• Certificate transfer pilot. The city will explore a pilot program for transferring medical device registration certificates.
• Offshore devices first-use trial. For devices already marketed abroad but unregistered in China and clinically urgent, Shanghai will explore allowing trial use in the city ahead of domestic registration.
• Shared infrastructure. Qualified device manufacturers within the same industrial park may share testing facilities and process water and gas equipment.
• Cross-province logistics. Eligible medical device logistics providers may set up warehouses across provincial lines under regulation.

For BCI developers, the practical consequence is a regulatory environment in which premarket standards, electrode test methods and post-market surveillance are designed as one connected pipeline rather than separate gates. Firms working on intracranial or implantable neural interfaces with Shanghai operations stand to gain a defined route for novel electrode characterization and faster review under the linkage mechanism.

The "15th Five-Year" planning horizon places implementation across the coming five-year cycle. Whether the dedicated BCI standards system and electrode evaluation methods arrive as mandatory national standards or municipal technical guidance will determine how binding the framework becomes for manufacturers seeking approval in China's largest device manufacturing hub.